DOI: 10.36347/sjams.2017.v05i03.020

Pages: 787-795

The objective is to investigate the long term effects of androgen deprivation therapy and non-androgen deprivation therapy on various metabolic risk factors in prostate carcinoma patients. It was a hospital based prospective study consisted of eighty eight subjects with diagnosed prostate carcinoma and twenty five aged matched healthy controls for the comparison of basic parameters at the initial level. The prostate carcinoma subjects were divided into two groups on the basis of metastatic prostate carcinoma and locally confined prostate carcinoma viz. androgen deprivation therapy (n=51) and non-androgen deprivation therapy (n=37). The subjects were examined for Adult Treatment Panel III criteria for metabolic syndrome. Anthropometric parameters were measured and biochemical parameters estimated at baseline and after 12 and 18 months of therapy. The anthropometric and biochemical parameters were significantly increased and insulin sensitivity was significantly decreased in androgen deprivation therapy group after the therapy of 18 months. However, in non-androgen deprivation group this change was non-significant. The results of the present study suggest that men with prostate carcinoma who receive androgen deprivation therapy develop insulin resistance and hyperglycemia as compared to those who received non androgen deprivation therapy. Hence, it may be stated that androgen deprivation therapy increases the metabolic burden. However, the level of high density lipoprotein also increases significantly in androgen deprivation therapy group which shows the difference with classical metabolic syndrome.